STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial
SPRING HOUSE, PENNSYLVANIA, July 9, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new three-year data from the long-term extension (LTE) of the STELARA® (ustekinumab) Phase 3 UNIFI study. The data demonstrated the majority (55.2 percent) of adult patients with moderately to severely active ulcerative colitis (UC) who initially responded to treatment with STELARA sustained symptomatic remissiona rates at nearly three years (week 152).1 Furthermore, a majority (96.4 percent) of the patients in symptomatic remissiona at week 152 were corticosteroid-free. These data are being presented...
Source: Johnson and Johnson - July 9, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Interleukin-6 antagonists improve outcomes in hospitalised COVID-19 patients
Findings from a study published today [6 July] in the Journal of the American Medical Association (JAMA) have prompted new World Health Organization (WHO) recommendations to use interleukin-6 antagonists in patients with severe or critical COVID-19 along with corticosteroids. (Source: University of Bristol news)
Source: University of Bristol news - July 6, 2021 Category: Universities & Medical Training Tags: Alumni, Health, International, Postgraduate, Public engagement, Publications, Research; Faculty of Health Sciences, Bristol Medical School, Faculty of Health Sciences, Population Health Sciences; Press Release Source Type: news
Interleukin-6 antagonists improve outcomes in hospitalised COVID-19 patients
(King's College London) Findings from a study published today [6 July] in the Journal of the American Medical Association (JAMA) have prompted new World Health Organization (WHO) recommendations to use interleukin-6 antagonists in patients with severe or critical COVID-19 along with corticosteroids. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 6, 2021 Category: International Medicine & Public Health Source Type: news
Medical costs higher for RA patients receiving corticosteroids and those with DM in Japan
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 1, 2021 Category: Drugs & Pharmacology Source Type: news
Roche's Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for intravenous Actemra/RoActemra® (tocilizumab) for the treatment of COVID-19 in hospitalised adults and paediatric patients (two years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). (Source: World Pharma News)
Source: World Pharma News - June 25, 2021 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news
Roche ’s Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children
Basel, 25 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for intravenous Actemra/RoActemra ® (tocilizumab) for the treatment of COVID-19 in hospitalised adults and paediatric patients (two years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). The E UA is based on results from four randomised, controlled studies that evaluated Actemra/RoActemra for the treatment of COVID-1...
Source: Roche Media News - June 25, 2021 Category: Pharmaceuticals Source Type: news
Roche ’s Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children
Basel, 25 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for intravenous Actemra/RoActemra ® (tocilizumab) for the treatment of COVID-19 in hospitalised adults and paediatric patients (two years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). The E UA is based on results from four randomised, controlled studies that evaluated Actemra/RoActemra for the treatment of COVID-1...
Source: Roche Investor Update - June 25, 2021 Category: Pharmaceuticals Source Type: news
US, International MIS-C Studies Yield Disparate Results US, International MIS-C Studies Yield Disparate Results
Both show that current treatments are effective, but one found better outcomes with immunoglobulin plus corticosteroid therapy, the other, no difference with combination therapy vs single-agent treatments.Medscape Medical News (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - June 17, 2021 Category: Emergency Medicine Tags: Pediatrics News Source Type: news
Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX ® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® (daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.[1] These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing and w...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
COVID-19 news from Annals of Internal Medicine
(American College of Physicians) Experts suggest limited and careful use of corticosteroids as one of several strategies to curtail the syndemic of mucormycosis, or 'black fungus,' a fungal infection characterized by blackening or discoloration over the face, breathing difficulties, and other serious symptoms, that has recently emerged in India. A commentary from Washington University School of Medicine and the University of Massachusetts Medical School is published in Annals of Internal Medicine. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 7, 2021 Category: Infectious Diseases Source Type: news
What Are Some Indications for Using Dexamethasone?
Discussion
Corticosteroids are a group of drugs which can be naturally or synthetically produced. Naturally occurring substances are produced in the adrenal gland, and are protein-bound (primarily corticosteroid-binding globulin and albumin). In the target tissues, they may need to be converted to an active substance. They are then reduced, oxidized, hydroxylated or conjugated as measures to inactivate them. Synthetic steroids have less protein binding and depending on their structure are more or less resistant to inactivation. Prednisone is the glucocorticoid most often used for treatment, especially as it has a short hal...
Source: PediatricEducation.org - June 7, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Mitigating the impacts of COVID-19: where are the mental health trials?, Lancet Psychiatry
COVID-19 prompted rapid mobilisation of health services and medical science in the face of unprecedented challenges. When COVID-19 emerged in 2020, medical science delivered, and delivered quickly. Using large-scale multicentre trials, researchers in partnership with health services established the ability of cheap and scalable interventions (such as corticosteroids) to save lives, and rapidly showed the futility of anecdotally endorsed repurposed drugs (such as hydroxychloroquine). The effectiveness of vaccinations was quickly established in phase 2 and 3 trials, providing the confidence to roll out successful vaccine pro...
Source: Current Awareness Service for Health (CASH) - June 4, 2021 Category: Consumer Health News Source Type: news
Drug-Induced Immunosuppression Examined in U.S. Adults
WEDNESDAY, June 2, 2021 -- Overall, 2.8 percent of a national cohort of commercially insured U.S. adults meet criteria for drug-induced immunosuppression, of whom 67.7 percent receive oral corticosteroids, according to a research letter published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 2, 2021 Category: Pharmaceuticals Source Type: news
Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A comp...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Add-On Voclosporin Improves Outcome in Lupus Nephritis Add-On Voclosporin Improves Outcome in Lupus Nephritis
Voclosporin plus MMF and low-dose corticosteroids improves renal response rates compared with use of these agents alone in patients with in lupus nephritis, according to a company-funded study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 1, 2021 Category: Consumer Health News Tags: Nephrology News Source Type: news
